The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Interleukin-6 in Rheumatoid Arthritis
Open accessAbstract
The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514 · cited 1×
“development of RA can be roughly distinguished into environmental and genetic, with the former influencing the second Overall, it is widely accepted that RA occurs in genetically predisposed individuals following the interaction with different environmental factors [19,20].”
BackgroundIL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Gregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., Wu, X., Li, J., Tang, L., Li, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3914 · Cited by 1,690
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Conti, P. (2020) · Journal of Biological Regulators and Homeostatic Agents · doi:10.23812/conti-e · Cited by 1,227
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Pro-inflammatory cytokines: The link between obesity and osteoarthritis
Wang, T., & He, C. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.002 · Cited by 1,034
CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 9×
“DMARDs normally used in RA do not always offer satisfactory results.”
BackgroundInfluentialJones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102452 · Cited by 763
Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D., & Kishimoto, T. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068064 · Cited by 727
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
One year in review 2020: pathogenesis of rheumatoid arthritis
Giannini, D., Antonucci, M., Petrelli, F., Bilia, S., Alunno, A., & Puxeddu, I. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/3uj1ng · Cited by 588
The pathogenicity of Th17 cells in autoimmune diseases
Yasuda, K., Takeuchi, Y., & Hirota, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00733-8 · Cited by 555
Matcham, F., Scott, I. C., Rayner, L., Hotopf, M., Kingsley, G. H., Norton, S., Scott, D. L., & Steer, S. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.001 · Cited by 525
Raza, K., Falciani, F., Curnow, S. J., Ross, E. J., Lee, C.-Y., Akbar, A. N., Lord, J. M., Gordon, C., Buckley, C. D., & Salmon, M. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1733 · Cited by 515
Interleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose-John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 509
van Rhee, F., Wong, R. S., Munshi, N., Rossi, J.-F., Ke, X.-Y., Fosså, A., Simpson, D., Capra, M., Liu, T., Hsieh, R. K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70319-5 · Cited by 454
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
2009 Pandemic Influenza A (H1N1)
Shieh, W.-J., Blau, D. M., Denison, A. M., DeLeon-Carnes, M., Adem, P., Bhatnagar, J., Sumner, J., Liu, L., Patel, M., Batten, B., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100115 · Cited by 429
Kremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 409
Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro.
Ishibashi, T., Kimura, H., Uchida, T., Kariyone, S., Friese, P., & Burstein, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5953 · Cited by 407
Interleukin-6 as a Therapeutic Target
Rossi, J.-F., Lu, Z.-Y., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366
Historical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srirangan, S., & Choy, E. H. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10378372 · Cited by 357
Samson, M., Audia, S., Janikashvili, N., Ciudad, M., Trad, M., Fraszczak, J., Ornetti, P., Maillefert, J., Miossec, P., & Bonnotte, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34477 · Cited by 347
One year in review 2021: pathogenesis of rheumatoid arthritis
Testa, D., Calvacchi, S., Petrelli, F., Giannini, D., Bilia, S., Alunno, A., & Puxeddu, I. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/j1l5l3 · Cited by 314
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
Kerschbaumer, A., Sepriano, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W. J., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216656 · Cited by 293
The many facets of macrophages in rheumatoid arthritis
Siouti, E., & Andreakos, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.029 · Cited by 248
The role and therapeutic targeting of IL-6 in rheumatoid arthritis
Narazaki, M., Tanaka, T., & Kishimoto, T. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1295850 · Cited by 217
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Sano, Y., Yaguramaki, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130466 · Cited by 208
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
Kim, G. W., Lee, N. R., Pi, R. H., Lim, Y. S., Lee, Y. M., Lee, J. M., Jeong, H. S., & Chung, S. H. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0569-8 · Cited by 202
The Two-Faced Cytokine IL-6 in Host Defense and Diseases
Narazaki, M., & Kishimoto, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113528 · Cited by 201
Key Role of DAMP in Inflammation, Cancer, and Tissue Repair
Pandolfi, F., Altamura, S., Frosali, S., & Conti, P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.02.028 · Cited by 189
Self-citationEffects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
Wright, H. L., Cross, A. L., Edwards, S. W., & Moots, R. J. (2014) · Rheumatology · doi:10.1093/rheumatology/keu035 · Cited by 185
Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar‐Pinheiro, G. D. R., Brzezicki, J., Hrycaj, P., Graham, N. M. H., van Hoogstraten, H., Bauer, D., & Burmester, G. R. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39944 · Cited by 178
IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?
Camporeale, A. (2012) · Frontiers in Bioscience · doi:10.2741/4054 · Cited by 176
Persson, G. R. (2012) · Journal of Oral Microbiology · doi:10.3402/jom.v4i0.11829 · Cited by 165
Burmester, G. R., Feist, E., Kellner, H., Braun, J., Iking-Konert, C., & Rubbert-Roth, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139725 · Cited by 164
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
Biggioggero, M., Crotti, C., Becciolini, A., & Favalli, E. G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s150580 · Cited by 157
Espina, M. D. T., Gabarrini, G., Harmsen, H. J. M., Westra, J., Winkelhoff, A. J. V., & van Dijl, J. M. (2018) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuy035 · Cited by 148
Down Syndrome and COVID-19: A Perfect Storm?
Espinosa, J. M. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100019 · Cited by 146
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rubbert‐Roth, A., Furst, D. E., Nebesky, J. M., Jin, A., & Berber, E. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0102-x · Cited by 145
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
Raimondo, M. G., Biggioggero, M., Crotti, C., Becciolini, A., & Favalli, E. G. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s100302 · Cited by 126
Management of cytokine release syndrome related to CAR-T cell therapy
Chen, H., Wang, F., Zhang, P., Zhang, Y., Chen, Y., Fan, X.-H., Cao, X.-M., Liu, J., Yang, Y., Wang, B., et al. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0714-8 · Cited by 123
A comprehensive review of rituximab therapy in rheumatoid arthritis patients
Tavakolpour, S., Alesaeidi, ., Darvishi, M., Ghasemiadl, M., Darabi-Monadi, S., Akhlaghdoust, M., Behjati, S. E., & Jafarieh, A. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04699-8 · Cited by 117
Rutherford, A. I., Subesinghe, S., Hyrich, K. L., & Galloway, J. B. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212825 · Cited by 109
Tocilizumab in the treatment of rheumatoid arthritis and beyond
Shetty, A., Hanson, R. L., Korsten, P., Shawagfeh, M., Arami, S., Volkov, S., Vila, O. M., Swedler, W., Shunaigat, A. N., Smadi, S., et al. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s41437 · Cited by 108
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis
Lamb, Y. N., & Deeks, E. D. (2018) · Drugs · doi:10.1007/s40265-018-0929-z · Cited by 100
Xu, Z., Bouman‐Thio, E., Comisar, C. M., Frederick, B., van Hartingsveldt, B., Marini, J. C., Davis, H. M., & Zhou, H. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03964.x · Cited by 99
Weinblatt, M. E., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., Xing, J., Zilberstein, M., Banerjee, S., & Emery, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39249 · Cited by 98
Gottenberg, J., Dayer, J., Lukas, C., Ducot, B., Chiocchia, G., Cantagrel, A. G., Saraux, A., Roux‐Lombard, P., & Mariette, X. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200975 · Cited by 94
Magyari, L., Varszegi, D., Kovesdi, E., Sarlos, P., Farago, B., Javorhazy, A., Sumegi, K., Banfai, Z., & Melegh, B. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i4.516 · Cited by 94
Chen, L.-F., Mo, Y., Jing, J., Ma, J.-D., Zheng, D.-H., & Dai, L. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13010 · Cited by 89
One year in review 2018: pathogenesis of rheumatoid arthritis.
Calabresi, E., Petrelli, F., Bonifacio, A. F., Puxeddu, I., & Alunno, A. (2018) · PubMed · Cited by 82
Involvement of Autoimmunity in the Pathogenesis of Aggressive Periodontitis
Hendler, A., Mulli, T., Hughes, F. J., Perrett, D. I., Bombardieri, M., Houri‐Haddad, Y., Weiss, E. I., & Nissim, A. (2010) · Journal of Dental Research · doi:10.1177/0022034510381903 · Cited by 75
Re, L., Baeza-Noci, J., Serra, M. E. G., Mollica, P. J., Bonetti, M., & Travagli, V. (2020) · PubMed · Cited by 72
Cross-Talk Between IL-1 and IL-6 Signaling Pathways in Rheumatoid Arthritis Synovial Fibroblasts1
Deon, D., Ahmed, S. T., Tai, K., Scaletta, N., Herrero, C., Lee, I.-H., Krause, A., & Ivashkiv, L. (2001) · Journal of Immunology · doi:10.4049/jimmunol.167.9.5395 · Cited by 69
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
Avcı, A. B., Feist, E., & Burmester, G. R. (2018) · BioDrugs · doi:10.1007/s40259-018-0320-3 · Cited by 63
van Rhee, F., Casper, C., Voorhees, P. M., Fayad, L., Gibson, D., Kanhai, K. J. K., & Kurzrock, R. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30257-1 · Cited by 63
Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis
Malemud, C. J. (2018) · Cells · doi:10.3390/cells7120223 · Cited by 62
Takeuchi, T., Tanaka, Y., Yamanaka, H., Amano, K., Nagamine, R., Park, W., Shiozawa, K., Tsukano, M., Wei, J. C., Shao, J., et al. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1074648 · Cited by 61
Santos-Savio, A., Diaz, A. C. M., Chico-Capote, A., Miranda-Navarro, J., Alvarez, Y. R., Bringas-Pérez, R., del Toro, M. E., & Nieto, G. G. G. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0516-3 · Cited by 56
Chi, G., Feng, X., Ru, Y.-X., Xiong, T., Gao, Y. H., Wang, H., Luo, Z., Mo, R., Guo, F., He, Y., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.005 · Cited by 45
Treatment of adult-onset still’s disease: up to date
Yoo, D. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1332994 · Cited by 42
A Review of Sarilumab for the Treatment of Rheumatoid Arthritis
Lee, E. B. (2017) · Immunotherapy · doi:10.2217/imt-2017-0075 · Cited by 36
Thrombopoietin Production in Wild-Type and Interleukin-6 Knockout Mice with Acute Inflammation
Burmester, H., Wolber, E., Freitag, P., Fandrey, J., & Jelkmann, W. (2005) · Journal of Interferon and Cytokine Research · doi:10.1089/jir.2005.25.407 · Cited by 34
Biologicals in rheumatoid arthritis: current and future
Avcı, A. B., Feist, E., & Burmester, G. R. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000127 · Cited by 32
Batún-Garrido, J. A. D. J., Salas‐Magaña, M., & Juárez‐Rojop, I. E. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3897-x · Cited by 31
Rationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review
Villani, E. R., Ranaldi, G. T., & Franza, L. (2020) · Medical Gas Research · doi:10.4103/2045-9912.289462 · Cited by 19
Self-citationInfectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition
Liu, A. Y. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.003 · Cited by 18
Meley, D., Héraud, A., Gouilleux‐Gruart, V., Ivanés, F., & Velge-Roussel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00926 · Cited by 17
&NA; (2003) · BioDrugs · doi:10.2165/00063030-200317050-00006 · Cited by 16
Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018
Bartoli, F., Bae, S. S., Cometi, L., Matucci‐Cerinic, M., & Furst, D. E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1487291 · Cited by 14
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study
Thorne, C., Takeuchi, T., Karpouzas, G. A., Sheng, S., Kurrasch, R., Fei, K., & Hsu, B. L. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000731 · Cited by 11
Franza, L., Carusi, V., Altamura, S., Gasbarrini, A., Caraffa, A., Kritas, S. K., Ronconi, G., Gallenga, C. E., Virgilio, F. D., & Pandolfi, F. (2019) · PubMed · Cited by 7
Self-citationTocilizumab for juvenile idiopathic arthritis: a single-center case series
Yazılıtaş, F., Özdel, S., Şimşek, D., Aydoğ, Ö., Çakıcı, E. K., Can, G. G., Güngör, T., & Bülbül, M. (2019) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2018.0489220719 · Cited by 6
Cited by
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases
Candelli, M., Franza, L., Pignataro, G., Ojetti, V., Covino, M., Piccioni, A., Gasbarrini, A., & Franceschi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126242 · Cited by 397
Self-citationInflammation and sarcopenia: A focus on circulating inflammatory cytokines
Pan, L., Xie, W., Fu, X., Lu, W., Jin, H., Lai, J., Zhang, A., Yu, Y., Li, Y., & Xiao, W. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111544 · Cited by 298
Metadata
- Authors
- Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-23
- Volume
- 21
- Issue
- 15
- Pages
- 5238
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3044289975
- Cited by
- 278
- References
- 85
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.